Liver failure
Conditions
Interventions
Experimental group:Nalimolimat mesylate
The control group:Ordinary heparin
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 18<=Age<70 years old, regardless of gender; 2. Patients who have been diagnosed with chronic acute liver failure caused by the Hepatitis B virus; 3. Voluntarily participate in this clinical trial and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Contraindications to treatment (? INR>2.5, platelets<20 × 109/L, severe active bleeding or combined with severe disseminated intravascular coagulation; ? Liver failure, with frequent symptoms such as irreversible respiratory failure, severe brain edema, and cerebral hernia; ? Patients with circulatory dysfunction who have not improved after comprehensive treatment such as fluid resuscitation and vasoactive drugs (excluding sepsis related liver damage) 2. Those with mental illness or other reasons who cannot cooperate with treatment; 3. Those who need to receive other anticoagulants due to treatment reasons; 4. Individuals with allergic constitution, known to be allergic to blood products, experimental drugs (napalmistat mesylate, heparin sodium), and their excipients; 5. Pregnant, recently preparing for pregnancy, and lactating women; 6. Those who have participated in other clinical trials within the past month; 7. The researcher believes that there are other unsuitable candidates for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of successful treatments completed; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of bleeding events;Number of clotting events;Liver function indicators;Extracorporeal circulation pressures;Coagulation function parameters;All-cause mortality rates and survival rates;Adverse events; | — |
Countries
China
Contacts
Public ContactLang Bai
West China Hospital of Sichuan University
Outcome results
None listed